Design and Optimization of Orodispersible Mucoadhesive Films of Nitrazepam Using Quality by Design (QbD) for Enhanced Neurotherapeutic Onset

This study presents the design and optimization of orodispersible mucoadhesive films (ODFs) of Nitrazepam utilizing a
Quality by Design (QbD) approach to achieve rapid neurotherapeutic onset and improved patient compliance. Nitrazepam,
a BCS Class II benzodiazepine with low aqueous solubility and extensive first-pass metabolism, poses challenges for
conventional oral delivery systems, especially in acute neurological conditions requiring rapid pharmacological intervention.
To address this, solvent casting was employed to formulate polymeric films using Hydroxypropyl Methylcellulose (HPMC
E5), propylene glycol, sodium starch glycolate, and aspartame. A Central Composite Design (CCD) was applied using
Design Expert software to optimize critical formulation parameters. Films were evaluated for disintegration time, folding
endurance, surface pH, drug content, in-vitro release, and stability under accelerated conditions. The optimized formulation
exhibited rapid disintegration (25.1 ± 1.53 s), high folding endurance (205 ± 5), near-neutral pH (7.07 ± 0.19), and >97%
drug release within 10 minutes. Kinetic analysis confirmed non-Fickian (anomalous) transport governed by both diffusion
and polymer erosion mechanisms. FTIR confirmed drug-excipient compatibility, while stability studies validated the
formulation's physical integrity and potency over 30 days. The QbD-based methodology enabled rational design with
predictive control, ensuring batch robustness and scalability. Overall, the developed Nitrazepam ODF offers a clinically
viable alternative to conventional tablets, particularly in pediatric, geriatric, and emergency neuropsychiatric settings,
promising enhanced bioavailability, faster therapeutic onset, and superior patient-centric performance.